AI and Neurological Rare & Neuroimmune Diseases ── 2026-10-19
New papers on neurological rare and neuroimmune diseases and AI, collected from journal feeds, PubMed (searched across all journals) and OpenAlex (a public index used instead of Google Scholar), judged by Jev (an AI that makes language judgements): original research, AI central, which of 9 disease groups, treatment or trials, and then ranked by importance up to a daily limit. Journals are not filtered by impact factor; each paper shows its journal's IF-equivalent (OpenAlex two-year mean citedness) and the date of that value. Each entry shows the full original abstract.
Read by disease: Basic research（0） · ALS（0） · Parkinson's（1） · Hereditary neurodegeneration（0） · Neuromuscular（0） · Multiple sclerosis（0） · NMOSD/MOGAD（0） · Myasthenia gravis（0） · Autoimmune encephalitis/CIDP/GBS（0）
Neurodegeneration and neuroimmunology research and AI
No new qualifying paper for this issue.
ALS: treatment, trials and AI
No new qualifying paper for this issue.
Parkinson's disease and parkinsonism: treatment, trials and AI
- Abstract
Multimodal research-grade magnetic resonance imaging (MRI) scans show potential for differentiating Parkinson’s disease (PD) from multiple system atrophy (MSA), but clinical translation is limited by cost, acquisition time, and processing burden. Here, we developed a T1-weighted structural MRI-based machine learning model to differentiate Parkinsonism and generalized it to routine anisotropic 2D clinical MRI. Using a multicenter cohort of 969 participants, we employed a hierarchical discovery–verification–translation framework. While a multimodal benchmark model achieved an area under the receiver operating characteristic curve (AUROC) of 0.98, our streamlined unimodal T1-Top20 model achieved an AUROC of 0.93 for multiclass discrimination (healthy controls, PD, MSA). For PD vs MSA, the frozen T1-Top20 model achieved a pooled AUROC of 0.88 in the external research-grade cohort ( n = 227) and identified 19 of 25 who phenoconverted from idiopathic rapid eye movement sleep behavior disorder (iRBD) to PD. Importantly, the generalized model achieved a pooled AUROC of 0.84 in the clinical-MRI cohort (2D T1, n = 303), supporting its potential for clinical translation.
Journal IF-equivalent: 13.9 (OpenAlex 2-year mean citedness, value as of 2026-10-18, retrieved 2026-10-19; not the official Clarivate IF)Reference: Zhou L, Wang C, Zhu X, Zhang D, Wu J, Huang S, et al. Automated differentiation for parkinsonism using clinical structural MRI: A multicenter study. npj Digit Med. 2026 Oct 16 [Epub ahead of print]. doi:10.1038/s41746-026-03357-z.Checked: Abstract only
See all 1 Parkinson's papers →
Hereditary neurodegenerative diseases: treatment, trials and AI
No new qualifying paper for this issue.
Neuromuscular diseases (muscular dystrophy, SMA): treatment, trials and AI
No new qualifying paper for this issue.
Multiple sclerosis: treatment, trials and AI
No new qualifying paper for this issue.
NMOSD and MOGAD: treatment, trials and AI
No new qualifying paper for this issue.
Myasthenia gravis: treatment, trials and AI
No new qualifying paper for this issue.
Autoimmune encephalitis, CIDP and Guillain-Barre syndrome: treatment, trials and AI
No new qualifying paper for this issue.